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Asymmetric catalysisAbstract A new class of low-cost and easy-to-prepare monodentate phosphite ligands has been
developed from readily accessible D-mannitol as starting material through a two-step transforma-
tion. Additionally, a simple and reliable protocol to synthesize neutral ruthenium phosphite com-
plexes is reported. Four new [RuCl2(p-cymene)(L)] complexes were prepared by binding the
desired phosphite ligands with [RuCl2(p-cymene)]2 individually in 89–96% isolated yield. The
desired Ru-complex 1 revealed full conversion (100%) with good enantioselectivity (ee: 73%,
83% isolated yields) toward asymmetric hydrogenation of a,a,a-triﬂuoroacetophenone.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Transition-metal-catalyzed transformations have become ex-
tremely powerful tools in asymmetric organic synthesis and
many classes of chiral ligands have been developed over the last
decades (Jacobsen et al., 1999).Several approaches have been
focused on the development of new and more efﬁcient chiral li-
gands leading to remarkable achievements, for example chiral
phosphites have increased their potentiality as a subject of
growing interest in asymmetric catalysis in recent years (van
Leeuwen et al., 2011). Thus, in addition to their well-known
application in hydroformylation reactions (Babin and WO
Whiteker, 1992; Buisman et al., 1997; Die´guez et al., 2000;Kless et al., 1996),they have also been applied in moderate to
high enantioselective hydrogenation (Reetz and Neugebauer,
1999; Reetz and mehler 2000), hydrosilylation (Pastor and
Shum, 1998; Sasaki et al., 1993), conjugate addition (Pa`mies
et al., 2000; Yan et al., 1999; Yan et al., 2000; Zhao et al.,
2007; Zhao et al., 2010), hydroformylation (Hua et al., 2004),
hydrovinylation (Shi et al., 2005), intramolecular Heck reac-
tion (Imbos et al., 2003; Mata et al., 2007), amination, etheriﬁ-
cation (Leitner et al., 2005; Shu and Hartwig, 2004) and allylic
substitution reactions (Pretot and Pfaltz, 1998). The use of
homochiral phosphites also has a synthetic value due to the rel-
atively easy access from enantiopure alcohols. It is worth men-
tioning that the vast majority of these ligands are based on
BINOL, TADDOL, spiroindanediol, or achiral biphenol bear-
ing a chiral alcohol moiety or amine (Choi et al., 2004; Hua
et al., 2003,2004). Recently, we introduced a new class of chiral
monodentate phosphoramidite ligands and bidentate phospho-
rus ligands derived from readily accessible enantiopure axially
chiral D-mannitol units (Fig. 1) (Al-Majid et al., 2012). In con-
tinuation of our interest in this ﬁeld, herein we report a straight
Figure 1 D-mannitol derived phosphoramidites, phosphites and phosphite ruthenium complexes.
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gands as well as studied their synthetic utilities as key interme-
diates for the synthesis of novel phosphite ruthenium
complexes. The use of chiral phosphite–Ru complexes in cata-
lytic asymmetric hydrogenation has been examined.
2. General experimental
General: All the moisture and air-sensitive reactions were car-
ried out under an inert atmosphere of an argon-ﬁlled glove box
and standard Schlenk-line techniques. All the chemicals were
purchased from Sigma–Aldrich, Fluka etc., and were used
without further puriﬁcation, unless otherwise stated.
CH2Cl2 dried from CaH2. Silica gel (SiO2; 100–200 mesh)
was used for Flash column chromatography. All melting
points were measured on a Gallenkamp melting point appara-
tus in open glass capillaries and are uncorrected. IR Spectra
were measured as KBr pellets on a Nicolet 6700 FT-IR spec-
trophotometer. The NMR spectra were recorded on a Jeol-
400 NMR spectrometer. 1HNMR (400 MHz), 13CNMR
(100 MHz) and 31PNMR were run in deuterated chloroform
(CDCl3). Chemical shifts (d) are referred in terms of ppm
and J-coupling constants are given in Hz. Mass spectra were
recorded on a Jeol JMS-600 H. Elemental analysis was carried
out on a Perkin Elmer 2400 Elemental Analyzer; CHN mode.
Optical rotations were measured on a Polarimeter, P8000 oper-
ating at the sodium D line with a 100 mm path length cell.
2.1. General procedure for the synthesis of chiral monodentate
phosphite ligands L1–L8 (general procedure A)
Triethylamine (971 lL, 7 mmol, 5.0 eq) was added drop wise
to a solution of freshly-distilled phosphorus trichloride
(123 lL, 1.4 mmol, 1.0 eq) in dichloromethane (5 mL) at
0 C. The solution was warmed to room temperature and the
alcohol or thiol derivative (1.4 mmol, 1.0 eq) was added neat.
The mixture was stirred for 5 h, at which time DIOL I
(500 mg, 1.4 mmol, 1.0 eq) was added neat and the mixture
stirred overnight. The suspension was concentrated and the li-
gand puriﬁed by ﬂash chromatography on silica gel (hexane
with 1% triethylamine) to give the ligands L1–L8
2.1.1. (4aR,7aR,11aS,11bS)-6-(((1S,2S,5R)-2-isopropyl-5-
methylcyclohexyl)oxy)-2,10. diphenylhexahydrobis
([1,3]dioxino)[5,4-d:40,50-f][1,3,2]dioxaphosphepine (L1)
L1 was obtained from L-Menthol (218 mg, 1.4 mmol, 1.0 eq)
and DIOL I (500 mg, 1.4 mmol, 1.0 eq) according to thegeneral procedure A as oil (550 mg, 1.01 mmol, 72%).
a24D ¼ 37:5 o (c = 0.1 g/dL, CHCl3); 1H NMR (400 MHz,
CDCl3) d= 7.47–7.34(m, 10H, Ph), 5.50 (s, 2H, PhCH), 4.55
(m, 2H, CHO), 4.33 (q, 2H, OCH2), 4.22 (d, 2H, J= 8.8 Hz,
OCH2), 3.80 (m, 2H, CHOP), 2.16–2.06 (m, 1H, CHO), 1.67
(m, 1H, CH(CH3)2), 1.45–1.16 (m, 8H, Menthol), 0.92 (d,
J= 6.6 Hz, 3H, CH3), 0.81 (t, 6H, J= 6.6 Hz,, CH(CH3)2);
13CNMR (100 MHz, CDCl3): d= 137.3, 128.3, 126.2, 100.8,
82.6, 69.6, 31.7, 22.9, 22.1, 21.0, 20.9, 15.6; 31PNMR
(130 MHz, CDCl3): d= 134.35; IR (Nujol, cm
1) 3410, 1684,
1619. GC–MSm/z (rel intensity) 543.61 (M+ 1)+; Anal. Calcd
for C30H39O7P: C, 66.41; H, 7.24. Found: C, 66.52; H, 7.25.
2.1.2. (4aR,7aR,11aS,11bS)-6-(naphthalen-1-yloxy)-2,10-
diphenylhexahydrobis([1,3]dioxino)[5,4-d:40,50-f][1,3,2]
dioxaphosphepine (L2)
L2 was obtained from 1-naphthol (202 mg, 1.4 mmol, 1.0 eq)
and DIOL I (500 mg, 1.4 mmol, 1.0 eq) according to the gen-
eral procedure A as yellowish solid (430 mg, 0.81 mmol,
58%). m. p. 78; a24D ¼ 32 o (c = 0.1 g/dL, CHCl3); 1H
NMR (400 MHz, CDCl3) d= 8.12 (d, J= 8.0 Hz, 1H, naph-
thyl), 7.85 (d, J= 8.0 Hz, 1H, naphthyl), 7.66 (d, J= 8.0 Hz,
1H, naphthyl), 7.54–7.35 (m, 13H, Ph & naphthyl), 7.07 (d,
J= 8.0 Hz, 1H, naphthyl), 5.53 (s, 2H, PhCH), 4.33(m, 2H,
CHO), 4.26 (q, 2H, OCH2), 4.06 (d, 2H, J= 8.8 Hz, OCH2),
3.79 (m, 2H, CHOP);13CNMR (100 MHz, CDCl3):
d= 147.8, 134.9, 128.3, 127.4, 126.2, 125.6, 122.3, 115.1,
100.8, 80.6, 69.5, 61.8; 31PNMR (130 MHz, CDCl3):
d= 135.15; IR (Nujol, cm1) 1682, 1615. GC–MS m/z (rel
intensity) 531.49 (M+ 1)+; Anal. Calcd for C30H27O7P: C,
67.92; H, 5.13. Found: C, 67.91; H, 5.10.
2.1.3. (4aR,7aR,11aS,11bS)-6-([1,10-biphenyl]-4-yloxy)-2,10-
diphenylhexahydrobis([1,3]dioxino)[5,4-d:4’,5’-f][1,3,2]
dioxaphosphepine (L3)
L3 was obtained from4-hydroxy-biphenol (238 mg, 1.4 mmol,
1.0 eq) and DIOL I (500 mg, 1.4 mmol, 1.0 eq) according to
the general procedure A as yellowish solid (250 mg, 0.45 mmol,
32%).m. p. 58; a24D ¼ 31 o (c = 0.1 g/dL, CHCl3); 1H NMR
(400 MHz, CDCl3) d= 7.57 (d, J= 1.5 Hz, 4H, biphenyl),
7.50–7.31 (m, 13H, Ph & biphenyl), 7.07 (d, J= 8.0 Hz, 2H,
biphenyl), 5.53 (s, 2H, PhCH), 4.57(m, 2H, CHO), 4.24 (q,
2H, OCH2), 4.06 (d, 2H, J= 8.8 Hz, OCH2), 3.78 (m, 2H,
CHOP);13CNMR (100 MHz, CDCl3): d= 150.9, 140.8,
134.8, 134.3, 129.1, 128.8, 127.2, 127.0, 126.9, 126.2, 121.1,
100.8, 80.6, 69.5; 31PNMR (130 MHz, CDCl3): d= 134.67;
IR (Nujol, cm1) 1689, 1620.GC–MS m/z (rel intensity)
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2.1.4. (4aR,7aR,11aS,11bS)-6-phenoxy-2,10-
diphenylhexahydrobis([1,3]dioxino)[5,4-d:40,50-
f][1,3,2]dioxaphosphepine (L4)
L4 was obtained from phenol (132 mg, 1.4 mmol, 1.0 eq) and
DIOL I (500 mg, 1.4 mmol, 1.0 eq) according to the general
procedure A as a yellowish solid (300 mg, 0.62 mmol,
45%).m. p. 53; a24D ¼ 27:6 o (c = 0.1 g/dL, CHCl3); 1H
NMR (400 MHz, CDCl3) d= 7.48–7.30 (m, 10H, 2Ph),
7.15–6.9 (m, 5H, Ph), 5.52 (s, 2H, PhCH), 4.58(m, 2H,
CHO), 4.24 (q, 2H, OCH2), 3.97 (d, 2H, J= 8.8 Hz, OCH2),
3.78 (m, 2H, CHOP); 13CNMR (100 MHz, CDCl3):
d= 152.6, 137.5, 128.7, 126.3, 124.5, 121.1, 109.2, 100.3,
78.9, 67.2; 31PNMR (130 MHz, CDCl3): d= 134.65; IR (Nu-
jol, cm1) 1685, 1621.GC–MS m/z (rel intensity) 481.45
(M+ 1)+; Anal. Calcd for C26H25O7P: C, 65.00; H, 5.24.
Found: C, 65.11; H, 5.34.
2.1.5. (4aR,7aR,11aS,11bS)-6-(benzyloxy)-2,10-
diphenylhexahydrobis([1,3]dioxino)[5,4-d:40,50-
f][1,3,2]dioxaphosphepine (L5)
L5 was obtained from benzyl alcohol (151 mg, 1.4 mmol,
1.0 eq) and DIOL I (500 mg, 1.4 mmol, 1.0 eq) according to
the general procedure A as a white solid (330 mg, 0.67 mmol,
48%).m. p. 63; a24D ¼ 25:9 o (c = 0.1 g/dL, CHCl3); 1H
NMR (400 MHz, CDCl3) d= 7.53–7.28 (m, 15H, 3Ph), 5.53
(s, 2H, PhCH), 4.87 (d, J= 8.0 Hz, 2H, PhCH2), 4.59(m,
2H, CHO), 4.22 (q, 2H, OCH2), 3.97 (d, 2H, J= 8.8 Hz,
OCH2), 3.79 (m, 2H, CHOP);
13CNMR (100 MHz, CDCl3):
d= 139.9, 137.5, 128.9, 127.8, 126.3, 110.8, 109.3, 109.5,
100.8, 78.9, 69.5, 63.4; 31PNMR (130 MHz, CDCl3):
d= 134.67; IR (Nujol, cm1) 1685, 1621. GC–MS m/z (rel
intensity) 495.47 (M+ 1)+; Anal. Calcd for C27H27O7P: C,
65.58; H, 5.50. Found: C, 65.63; H, 5.52.2.1.6. (4aR,7aR,11aS,11bS)-6-(furan-2-ylmethoxy)-2,10-
diphenylhexahydrobis([1,3]dioxino)[5,4-d:40,50-
f][1,3,2]dioxaphosphepine (L6)
L6 was obtained from furfuryl alcohol (137 mg, 1.4 mmol,
1.0 eq)and DIOL I (500 mg, 1.4 mmol, 1.0 eq) according to the
general procedure A as oil (350 mg, 0.72 mmol, 52%).
a24D ¼ 28:5 o (c = 0.1 g/dL, CHCl3); 1H NMR (400 MHz,
CDCl3) d= 7.65 (d, J= 8.8 Hz, 1H, Furan), 7.48–7.30 (m,
10H, 2Ph), 6.45 (d, J= 8.8 Hz, 1H, Furan), 6.40 (d,
J= 8.8 Hz, 1H, Furan), 5.53 (s, 2H, PhCH), 4.65 (d,
J= 8.0 Hz, 2H,PhCH2), 4.59 (m, 2H, CHO), 4.22 (q, 2H,
OCH2), 3.97 (d, 2H, J= 8.8 Hz, OCH2), 3.79 (m, 2H, CHOP);
13CNMR (100 MHz, CDCl3): d= 152.9, 143.8, 134.5, 128.9,
127.8, 126.3, 110.8, 109.3, 109.5, 100.8, 78.9, 69.5, 60.4; 31PNMR
(130 MHz, CDCl3): d= 132.50; IR (Nujol, cm
1) 1685,
1621.GC–MSm/z (rel intensity) 485.43 (M+ 1)+; Anal. Calcd
for C25H25O8P: C, 61.98; H, 5.20. Found: C, 62.00; H, 5.24.
2.1.7. (4aR,7aR,11aS,11bS)-6-(tert-butoxy)-2,10-
diphenylhexahydrobis([1,3]dioxino)[5,4-d:40,50-
f][1,3,2]dioxaphosphepine (L7)
L7 was obtained from t-Butanol (103 mg, 1.4 mmol,
1.0 eq)and DIOL I (500 mg, 1.4 mmol, 1.0 eq) according tothe general procedure A as oil (230 mg, 0.5 mmol, 36%).
a24D ¼ 19 (c = 0.1 g/dL, CHCl3); 1H NMR (400 MHz,
CDCl3) d= 7.50–7.35 (m, 10H, 2Ph), 5.54 (s, 2H, PhCH),
4.59 (m, 2H, CHO), 4.22 (q, 2H, OCH2), 3.96 (d, 2H,
J= 8.8 Hz, OCH2), 3.76 (m, 2H, CHOP), 1.44 (s, 9H,
3CH3);
13CNMR (100 MHz, CDCl3): d= 137.3, 129.3, 128.3,
126.2, 101.1, 82.6, 69.8, 61.8, 31.2; 31PNMR (130 MHz,
CDCl3): d= 131.77; IR (Nujol, cm
1) 1685, 1621. GC–MS
m/z (rel intensity) 461.46 (M+, 1); Anal. Calcd for
C24H29O7P: C, 62.60; H, 6.35. Found: C, 62.58; H, 6.34.
2.1.8. (4aR,7aR,11aS,11bS)-2,10-diphenyl-6-(phenylthio)
hexahydrobis([1,3]dioxino)[5,4-d:4’,5’-
f][1,3,2]dioxaphosphepine (L8)
L8 was obtained from thiophenol (154 mg, 1.4 mmol,
1.0 eq)and DIOL I (500 mg, 1.4 mmol, 1.0 eq) according to the
general procedure A as oil (275 mg, 0.55 mmol, 39%). a24D ¼
26:8 o (c = 0.1 g/dL, CHCl3); 1H NMR (400 MHz, CDCl3)
d= 7.48–7.29 (m, 15H, 3Ph), 5.54 (s, 2H, PhCH), 4.58(m, 2H,
CHO), 4.25 (q, 2H, OCH2), 3.97 (d, 2H, J= 8.8 Hz, OCH2),
3.80 (m, 2H, CHOP); 13CNMR (100 MHz, CDCl3):
d= 137.5, 135.7, 133.9, 129.5, 128.6, 127.6, 126.5, 125.4,
110.2, 78.5, 70.5, 69.3; 31PNMR (130 MHz, CDCl3):
d= 132.93; IR (Nujol, cm1) 1685, 1621. GC–MS m/z (rel
intensity) 497.51 (M+ 1)+; Anal. Calcd for C26H25O6PS: C,
62.89; H, 5.08; S, 6.46. Found: C, 62.60; H, 5.15; S, 6.45.
2.2. General procedure for the synthesis of chiral ruthenium
complexes (general procedure B)
A mixture of [RuCl2(g6-p-cymene)]2 (56 mg, 0.09 mmol), and
phoshite ligands L1, L3–L5 (115 mg, 0.18 mmol), in degassed
DCM (15 mL) was stirred at RT for 2 h, subsequently the sol-
vent was reduced to about 2–3 ml and the product was precip-
itated by the addition of n-pentane (20–25 ml). The orange
powder was ﬁltered, washed with pentane (2 · 5 ml) and dried
under vacuum.
2.2.1. Synthesis of [RuCl2(p-cymene)(L1)]. 1
1 was obtained from Ligand L1 (100 mg, 0.18 mmol) and
[RuCl2(g6-p-cymene)]2 (56 mg, 0.09 mmol) according to the
general procedure B as an orange powder (150 mg, 0.17 mmol,
96%); m.p. 132–135; a24D ¼ þ206 o (c= 0.1 g/dL, CHCl3); 1H
NMR (400 MHz, CDCl3) d= 7.55–7.30 (m, 14H, 2Ph & p-
cymene), 5.54 (s, 2H,PhCH), 4.52 (m, 2H, CHO), 4.37 (q,
2H, OCH2), 4.22 (d, 2H, J= 8.8 Hz, OCH2), 3.89 (m, 2H,
CHOP), 2.90(m, 1H, CH(CH3)2 of p-cymene), 2.38–2.11 (m,
1H, CHO), 2.14 (s, 3H, CH3) 1.73 (m, 1H, CH(CH3)2), 1.45–
1.16 (m, 8H, Menthol), 1.23 (d, 6H, J= 8.8 Hz, CH(CH3)2
of p-cymene), 0.92 (d, J= 6.6 Hz, 3H, CH3), 0.81 (t, 6H,
J= 6.6 Hz, CH(CH3)2);
13CNMR (100 MHz, CDCl3):
d= 137.3, 128.3, 128.2, 126.4, 100.8, 91.6, 81.8, 81.3, 80.6,
68.8, 49.4, 44.0, 34.0, 31.7, 30.7, 25.8, 22.2, 21.5, 16.5;
31PNMR (130 MHz, CDCl3): d= 113.26; IR (Nujol, cm
1)
3410, 1684, 1619. GC–MS m/z (rel intensity) 849.79
(M+ 1)+; Anal. Calcd for C40H53Cl2O7PRu: C, 56.60; H,
6.29. Found: C, 56.65; H, 6.35.
2.2.2. Synthesis of [RuCl2(p-cymene)(L4)]. 2
2 was obtained from Ligand L4 (85 mg, 0.18 mmol) and
[RuCl2(g6-p-cymene)]2 (56 mg, 0.09 mmol) according to the
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94%); m.p. 110–112; a24D ¼ þ213 o (c = 0.1 g/dL, CHCl3); 1H
NMR (400 MHz, CDCl3) d= 7.55–7.15 (m, 19H, 3Ph &
p-cymene), 5.52 (s, 2H,PhCH), 4.82 (m, 2H, CHO), 4.58 (q,
2H, OCH2), 4.09 (d, 2H, J= 8.8 Hz, OCH2), 3.68 (m, 2H,
CHOP), 2.92(m, 1H, CH(CH3)2 of p-cymene), 2.14 (s, 3H,
CH3) 1.22 (d, 6H, J= 8.8 Hz, CH(CH3)2 of p-cymene);
13CNMR (100 MHz, CDCl3): d= 152.7, 137.3, 128.3, 128.2,
126.4, 100.8, 91.6, 81.8, 81.3, 80.6, 68.8, 49.4, 44.0, 34.0,
31.7, 30.7, 25.8, 22.2, 21.5, 16.5; 31PNMR (130 MHz, CDCl3):
d= 118.23; IR (Nujol, cm1) 3410, 1684, 1619.GC–MS m/z
(rel intensity) 787.64 (M+ 1)+; Anal. Calcd for C36H39Cl2O7
PRu: C, 54.97; H, 5.00. Found: C, 55.08; H, 5.11.
2.2.3. Synthesis of [RuCl2(p-cymene)(L3)]. 3
3 was obtained from Ligand L3 (100 mg, 0.18 mmol) and
[RuCl2(g6-p-cymene)]2 (56 mg, 0.09 mmol) according to the
general procedure B as an orange powder (137 mg, 0.17 mmol,
95%); m.p. 145–147; a24D ¼ þ199 o (c = 0.1 g/dL, CHCl3); 1H
NMR (400 MHz, CDCl3) d= 7.55–7.30 (m, 23H, 3Ph &
p-cymene), 5.59 (s, 2H,PhCH), 4.69 (m, 2H, CHO), 4.398 (q,
2H, OCH2), 3.98 (d, 2H, J= 8.8 Hz, OCH2), 3.61 (m, 2H,
CHOP), 2.80(m, 1H, CH(CH3)2 of p-cymene), 1.95 (s, 3H,
CH3) 1.24 (d, 6H, J= 8.8 Hz, CH(CH3)2 of p-cymene);
13CNMR (100 MHz, CDCl3): d= 151.6, 140.9, 137.3, 128.3,
128.2, 126.4, 100.8, 91.6, 81.8, 81.3, 80.6, 68.8, 49.4, 44.0,
34.0, 31.7, 30.7, 25.8, 22.2, 21.5, 16.5; 31PNMR (130 MHz,
CDCl3): d= 122.47; IR (Nujol, cm
1) 3410, 1684, 1619.
GC–MS m/z (rel intensity) 863.74 (M+, 1); Anal. Calcd for
C42H43Cl2O7PRu: C, 58.47; H, 5.02. Found: C, 58.60; H, 5.00.
2.2.4. Synthesis of [RuCl2(p-cymene)(L5)]. 4
4 was obtained from Ligand L5 (90 mg, 0.18 mmol) and
[RuCl2(g6-p-cymene)]2 (56 mg, 0.09 mmol) according to the
general procedure B as an orange powder (130 mg, 0.16 mmol,
89%); m.p. 100–102; a24D ¼ þ202 o (c = 0.1 g/dL, CHCl3); 1H
NMR (400 MHz, CDCl3) d= 7.46–6.97 (m, 19H, 3Ph &
p-cymene), 5.46 (s, 2H, PhCH), 5.15 (d, 2H, J= 8.8 Hz,
CH2Ph), 4.88 (m, 2H, CHO), 4.58 (q, 2H, OCH2), 3.88 (d,
2H, J= 8.8 Hz, OCH2), 3.61 (m, 2H, CHOP), 2.88 (m, 1H,
CH(CH3)2 of p-cymene), 2.15 (s, 3H, CH3) 1.26 (d, 6H,
J= 8.8 Hz, CH(CH3)2 of p-cymene);
13CNMR (100 MHz,
CDCl3): d= 151.6, 140.9, 137.3, 128.3, 128.2, 126.4, 100.8,
91.6, 81.8, 81.3, 80.6, 68.8, 49.4, 44.0, 34.0, 31.7, 30.7, 25.8,
22.2, 21.5, 16.5; 31PNMR (130 MHz, CDCl3): d= 114.44;
IR (Nujol, cm1) 3410, 1684, 1619. GC–MS m/z (rel intensity)
801.67 (M+, 1); Anal. Calcd for C37H41Cl2O7PRu: C, 55.50;
H, 5.16. Found: C, 55.65; H, 5.38.Scheme 1 Synthesis of chiral mo2.3. General procedure for asymmetric hydrogenation of ketone
The appropriate amount of catalyst (1 mol%, 8.63 mg) in 5 ml
of 2-propanol, KOtBu (8 equiv. 9 mg, per Ru atom) was added
under nitrogen. The solution was stirred for 15 min at room
temperature. The ketone (174.12 mg, 1 mmol) was introduced
into the catalyst solution at 0.1 M (S/C = 100), the reduction
was conducted at room temperature under nitrogen for the
time indicated (monitored by GC). The resulting solution
was neutralized with 1 M HCl solution and concentrated in va-
cuo to give the crude product, which was puriﬁed by chroma-
tography (SiO2, hexane:EtOAc: 90:10). Yield 83%; ee 73%
was determined by HPLC nucleodex B-PM.
3. Results and discussion
3.1. Ligand synthesis
Recently, we reported a type of modular monodentate phos-
phoramidite ligand (Al-Majid et al., 2012). Despite the advan-
tages of excellent enantioselectivities and ﬁne-tuning capability
exhibited by these type of ligands, their syntheses were some-
what tedious. As an effort to develop low-cost and easy-to-pre-
pare phosphorus ligands which can still hold the advantages of
a phosphoramidite ligand, herein we report the design and syn-
thesis of a new class of modular monodentate phosphite li-
gands starting from very cheap and readily accessible DIOL I.
As shown in Scheme 1, the synthesis of monophosphorus
ligands L1–L8 was quite straightforward. The synthetic proce-
dure started with the reaction of alcohol derivatives with
freshly-distilled PCl3 and Et3N as base in DCM at 0C. The
resulting intermediate II was treated with one equivalent of
DIOLI. The monophosphorus ligands were obtained as
white-pale yellow foaming solids in moderate to very good
yields.
The ligands synthesized by this method are shown in
Table 1. Ligand L1 was substituted with a sterically demand-
ing L-menthyl group at phosphorus (Table 1, entry 1). To
the best of our knowledge, no such L-menthyl substituted
D-mannitol-based phosphite had been reported so far. This
new ligand L1 was separated in very good yield. Its formation
was conﬁrmed and elucidated by 1H, 13C and 31P NMR spec-
tra. This preliminary result encouraged us to prepare more li-
gands L2–L8 in one step using the same methodology. The 31P
NMR spectroscopic data for ligands L1–L8 are summarized in
Table 1. It was found that all phosphite ligands were obtained
in excellent isomer purity based on 31P NMR.nodentate phosphite ligands.
S898 A. Barakat, A.M. Al-MajidLigand L2 was obtained by a similar procedure with 1-
Naphthol, using the DCM as the reaction solvent. The
31PNMR analysis identiﬁed the major isomer at d= 134.67.
The steric hindrance is even more pronounced in ligand L3,
with biphenyl instead of naphthyl moieties in the DIOL back-
bone. This might also account for the rather poor chemical
yield (32% as compared to 58% of L2). Phosphite L4 (Table 1,
entry 4), and Phosphite L5 (Table 1, entry 5), were synthesized
using a similar strategy by reacting DIOL I with phenol and
benzyl alcohol in 45 and 48% yields respectively. Ligand L6
(Table 1, entry 6) is unprecedented with a furfuryl moiety, pro-
viding another Lewis basic coordination site. Introduction of t-
butyl of the DIOLs I scaffold would accomplish the same aims
as set out (Table 1, entry 7). Ligand L8 is a phenylthio DIOL
ligand derivative (Table 1, entry 8) in 39% yield.Table 1 D-mannitol derived chiral monodentate phosphite ligands
# Compound X–R
1 L1
O
2 L2
O
3 L3
O
4 L4
O
5 L5 O
6 L6 O
7 L7
O
8 L8
S
a Determined by 31PNMR.
b Isolated yield after column chromatography.3.2. Coordination studies
Having these phosphite ligands encouraged us to synthesize
phosphite complexes having a chiral backbone. Herein we de-
scribe the synthesis and structural characterization of ruthe-
nium phosphite complexes with the general formula
[RuCl2(p-cymene)(L)]. We applied them as catalysts in the
asymmetric hydrogenation of ketone. To achieve our objec-
tives, commercial [RuCl2(p-cymene)]2 seemed to be a suitable
precursor. It is known that the commercial ruthenium precur-
sor [RuCl2(p-cymene)]2 forms ruthenium complexes with the
general formula [RuCl2(p-cymene)(L)] when treated with phos-
phoramidite ligands (Costin et al., 2008; Huber et al., 2006).
Accordingly, the phosphite ligand L1 was reacted with an
0.5 M amount of [RuCl2(p-cymene)]2 under standardL1–L8.
dPa Yieldb
134.35 72
134.67 58
Ph
134.67 32
134.65 45
134.67 48
O
132.50 52
131.77 36
132.93 39
Scheme 2 Synthesis of phosphite ruthenium complexes.
Table 2 D-Mannitol derived phosphite ruthenium complexes.
# Compound X–R dPa Yieldb
a 1
O
113.26 96
b 2
O
118.23 94
c 3
O Ph
122.47 95
d 4 O 114.44 89
a Determined by 31PNMR.
b Isolated yield.
Scheme 3 Asymmetric hydrogenation of ketone.
Synthesis, structural characterization of monodentate phosphite ligands and phosphite S899conditions (CH2Cl2, room temperature, 2 h, as shown in
Scheme 2). The corresponding arene ruthenium complex 1
was obtained as a tan orange solid in 96% yield.
Employing a similar protocol with ligands L3–L5, the cor-
responding ruthenium complexes 2, 3 and 4 were synthesized
in 94%, 95%and 89% yields, respectively (Table 2, entry b,
c, and d). The novel metal complexes 1–4 were analyzed by
NMR (1H, 13C, 31P), IR, and mass spectrometry. The 4 arene
ruthenium complexes 1, 2, 3 and 4 were precipitated by the
addition of pentane and the orange yellow powder was ﬁltered,
washed with pentane and dried under vacuum. The solid prod-
ucts were used for microanalysis without further puriﬁcation.
The coordination of the monodentate phosphite ligand was
best seen by a shift of their 31P NMR signals in the spectra of
their corresponding metal complexes. For example, the free
phosphite ligand L5 showed a 31P NMR signal at
134.67 ppm, whereas its corresponding metal complex 4 was
downﬁeld to 114.44 ppm .
3.3. Asymmetric hydrogenation of ketone
In the past few years, a group of less electron-rich phosphorus
compounds, phosphite containing ligands, have demonstrated
their huge potential utility in many transition-metal catalyzed
reactions (Claver et al., 2006; Die´guez et al., 2004; Pa`mies
et al., 2005). Their highly modular construction, facile synthe-
sis from readily available chiral alcohols and greater resistance
to oxidation than phosphines have proved to be highly advan-
tageous. Based on these preliminary results we present the
application of a phosphite-ruthenium complex for the asym-
metric hydrogenation of ketone (Scheme 3).
Utilizing 1 mol% cat of 1, 8.0 equiv. of KOt-Bu, in i-PrOH
and the reaction mixture was stirred at RT for 24 h. Under
these conditions, the reaction was successful and the
corresponding alcohol was formed. The catalyst 1, bearing
L-menthyl group at of the DIOL backbone-Ru complex, gave
high yield (83%) and good enantioselectivity (73% ee) at room
temperature. To the best of our knowledge, the technology for
the catalytic asymmetric reduction of ketones now covers a
large spectrum of substrates, including highly complex and
functionalized molecules (Gerosa et al., 2005). The process is
economically viable for the industrial production of pharma-
ceutical intermediates. A wide range of catalysts based on
well-established ligands produced on multi-kilo scale is avail-
able and the scope of the reactions is continually expanding,
especially with the discovery of ruthenium catalysts based onnew combinations of ligands. However, developments are still
needed and new technology required to meet the challenges of
processes, such as the hydrogenation of aliphatic ketones and
S900 A. Barakat, A.M. Al-Majidreductive amination. The development of new ligands and cat-
alysts will remain a ‘‘hot topic’’ in research for many years to
come.
4. Conclusions
The strategy described in this paper to discover new chiral cat-
alysts–the tuning of the performance of the catalyst by modi-
fying the steric and electronic properties of the molecular
fragments or modules–is based on a correct hypothesis. We
have developed a new class of chiral phosphiteligands derived
from D-mannitol. Coordination studies of the ruthenium phos-
phite complexes were also carried out. We have shown an
example of the asymmetric hydrogenation of a,a,a-triﬂuoro-
acetophenone here with up to 73% ee. Future work is in pro-
gress, applying these ligands toward new asymmetric reactions,
such as allylic substitutions, conjugate addition or in hydroge-
nations of challenging substrate classes (containing C‚N and
unfunctionalized C‚C bonds).Acknowledgments
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